Sirona Biochem Corp. (V:SBM*CA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: Sirona Biochem Corp. (c/o WeWork)
595 Burrard St.
Tel: N/A
IR: See website
Key People
Howard Verrico
Chairman of the Board, Interim Chief Executive Officer, Founder, Secretary
Christopher D. Hopton
Chief Financial Officer, Director
Geraldine Deliencourt-Godefroy
Chief Scientific Officer, Director
Attila Hajdu
Chief Business Development Officer
Business Overview
Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.
Financial Overview
For the six months ended 30 April 2019, Sirona Biochem Corp revenues decreased 89% to C$65K. Net loss increased from C$732K to C$1.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Consulting fees increase from C$84K to C$394K (expense), Share-based payments increase from C$79K to C$199K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $106.82M as of Apr 30, 2019
Annual revenue (TTM): $0.78M as of Apr 30, 2019
EBITDA (TTM): -$2.12M as of Apr 30, 2019
Net annual income (TTM): -$2.41M as of Apr 30, 2019
Free cash flow (TTM): -$2.05M as of Apr 30, 2019
Net Debt Last Fiscal Year: $1.57M as of Apr 30, 2019
Shares outstanding: 220,312,003 as of Sep 16, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization